$VVOS News

Last published 3w ago

3w agoVVOSVivos Therapeutics Reports Nasdaq Confirmation of Compliance with Continued Listing Shareholders’ Equity StandardGlobeNewswireLITTLETON, Colo., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a medical device and healthcare services company focused on developing and
3w agoVVOSVivos Therapeutics Closes Acquisition of Stake in SOD Sciences and 50% Interest in Pseudohypoxia Test, Opening a Potential Path to Access More Than 325,000 New Patients Through the AHA ChannelGlobeNewswireLITTLETON, Colo., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (NASDAQ:VVOS) ("Vivos" or the "Company") today announced that it has closed its acquisition of an 11% fully diluted equity
3w agoVVOSVivos Therapeutics Agrees to Acquire Minority Stake in SOD Sciences and 50% Interest in Proprietary Pseudohypoxia TestGlobeNewswireLITTLETON, Colo., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a medical device and healthcare services company focused on developing and
2mo agoVVOSVivos Therapeutics Announces Material Debt ReductionGlobeNewswireLITTLETON, Colo., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or "the Company") (NASDAQ:VVOS), a medical device and healthcare services company focused on developing and
2mo agoVVOSVivos Therapeutics and South Palm Cardiovascular Associates Sign Definitive Agreements to Launch Regional Sleep Testing and Treatment CenterGlobeNewswireLITTLETON, Colo., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or "the Company") (NASDAQ:VVOS), a leading medical device and healthcare services company focused on developing and
2mo agoVVOSVivos Therapeutics Reports Record New Patient Referrals at its Nevada Sleep & Airway Medicine CentersGlobeNewswireLITTLETON, Colo., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or "the Company") (NASDAQ:VVOS), a leading medical device and healthcare services company focused on developing and
2mo agoVVOSVivos Therapeutics Opens New Sleep Testing and Treatment Facility in Nevada to Meet Rapidly Growing Patient Demand for Sleep Apnea Testing and TreatmentGlobeNewswireNew Location Expected to More Than Double Annual Revenue Production Capacity to Over $10 Million Official Grand Opening Slated for August 27 in Henderson, Nevada With Prominent Industry Opinion Leaders, Sleep
2mo agoVVOSVivos Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational UpdateGlobeNewswireQuarter highlighted by steadily increasing patient demand for Vivos’ differentiated array of highly effective OSA treatments Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., Aug. 14, 2026
2mo agoVVOSVivos Therapeutics Schedules Release of Second Quarter 2026 Financial Results and Conference CallGlobeNewswireLITTLETON, Colo., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company’’) (NASDAQ:VVOS), a leading medical device and healthcare services company focused on developing and
3mo agoVVOSVivos Therapeutics Expands Greenway Health Partnership to Deploy AI-Enabled Platform Across All Clinical and Revenue OperationsGlobeNewswireGreenway analysis estimates AI-enabled automation in Nevada alone could create up to $9.0 million in potential annual value, including approximately $8.0 million from increased patient capacity and $1.0 million from
3mo agoVVOSVivos Therapeutics Announces Issuance of New US Patent Broadening Protection for Its Vivos CARE Oral Medical Device TechnologyGlobeNewswireLITTLETON, Colo., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or "the Company") (NASDAQ:VVOS), a leading medical device and healthcare services company focused on developing and
4mo agoVVOSVivos’ Vida® Appliance Shows Statistically Significant Improvement in Insomnia Severity in 100% of Study ParticipantsGlobeNewswireLITTLETON, Colo., June 30, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leading medical device and healthcare services company focused on the treatment
4mo agoVVOSVivos Therapeutics and Streeterville Extend Timeframe of Strategic Financing Agreement and Reaffirm Commitment to Convert Debt Into Common Stock and Perpetual Preferred EquityGlobeNewswireLITTLETON, Colo., June 22, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leading medical device and healthcare services company focused on the treatment
5mo agoVVOSVivos Therapeutics Announces Intent to File a Registration Statement for a Proposed Rights OfferingGlobeNewswireLITTLETON, Colo., June 11, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatment of
5mo agoVVOSVivos Therapeutics Announces Key Collaboration Agreement with Multi-Location Florida Cardiology Group to Extend Much Needed Sleep Apnea and Insomnia Diagnosis and Treatment to Cardiovascular PatientsGlobeNewswireLITTLETON, Colo., June 10, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leading medical device and healthcare services company focused on the treatment
5mo agoVVOSVivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026GlobeNewswireLITTLETON, Colo., June 08, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and healthcare services company focused on the treatment of
5mo agoVVOSVivos Therapeutics Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Streeterville Capital to Support Continued Nasdaq ListingGlobeNewswireLITTLETON, Colo., June 05, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and healthcare services company focused on the treatment of
5mo agoVVOSVivos Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational UpdateGlobeNewswireYear-over-year revenue increased 70%, reflecting contribution from Vivos' acquisition of The Sleep Center of Nevada Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., May 20, 2026 (GLOBE
7mo agoVVOSVivos Therapeutics Reports Full Year 2025 Financial ResultsGlobeNewswireFull Year 2025 revenue increased 16% Integration of The Sleep Center of Nevada and shift in business model support path to improved revenues, margins and cash flow Management to Host Conference Call today at 5:00 pm ET
7mo agoVVOSVivos Therapeutics Schedules Release of Full Year 2025 Financial Results and Conference CallGlobeNewswireLITTLETON, Colo., April 15, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leading medical device and healthcare services company focused on the treatment
7mo agoVVOSVivos Therapeutics Completes Private Placement with Existing Private Equity Investor, New Seneca PartnersGlobeNewswireLITTLETON, Colo., April 07, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leading medical device and healthcare services company focused on the treatment
7mo agoVVOSVivos Therapeutics Reports that Supported Professional Practices Have Achieved 'In-Network' Status Across Multiple Commercial Health Insurers and Medicare in Key Nevada MarketGlobeNewswireInsurance Coverage on Vivos Appliances and Treatment Now Available to a Significant Number of Nevada Patients Previously Unable to Access Coverage Concurrently, Vivos Implements Cost Reduction Initiatives Related to
9mo agoVVOSVivos Therapeutics and SoundHealth Announce Collaboration to Expand Access to SoundHealth's Groundbreaking FDA-Cleared Allergy and Sleep TechnologiesGlobeNewswireVivos adds more cutting-edge products to its roster serving the breathing and sleep wellness market LITTLETON, Colo., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'')
9mo agoVVOSVivos Therapeutics Announces Closing of Exercise of Warrants for $4.64 Million Gross ProceedsGlobeNewswireLITTLETON, Colo., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and healthcare services company focused on sleep related breathing
9mo agoVVOSVivos Therapeutics Announces Exercise of Warrants for $4.64 Million Gross ProceedsGlobeNewswireLITTLETON, Colo., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and healthcare services company focused on sleep related breathing
11mo agoVVOSVivos Therapeutics Announces Grand Opening of Affiliated Sleep Center Near Detroit, MichiganGlobeNewswireLITTLETON, Colo., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and healthcare services company focused on sleep related breathing
11mo agoVVOSVivos Therapeutics to Participate in Online Fireside Chat with Water Tower Research on December 16, 2025, at 11 am ESTGlobeNewswireLITTLETON, Colo., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and healthcare services company specializing in the delivery of highly
11mo agoVVOSVivos Therapeutics Reports Significant Revenue Growth During the Third Quarter 2025GlobeNewswireFinancial results highlighted by 78% sequential quarter over quarter revenue growth, showing the impact of the first full quarter of Sleep Center of Nevada operations Management to host conference call today at 5:00 pm
11mo agoVVOSVivos Therapeutics Schedules Release of Third Quarter 2025 Financial Results and Conference CallGlobeNewswireLITTLETON, Colo., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leading medical device and healthcare services company specializing in the delivery of highly
1y agoVVOSVivos Therapeutics Releases Additional Clinical Data Showing Marked Improvement in Pediatric ADHD from Use of Vivos DNA DeviceGlobeNewswireLITTLETON, Colo., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and
1y agoVVOSVivos Therapeutics Announces Landmark Clinical Trial Results in Pediatric Obstructive Sleep Apnea TreatmentGlobeNewswireLITTLETON, Colo., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and
1y agoVVOSVivos Therapeutics, Inc. (VVOS) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
1y agoVVOSVivos Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational UpdateGlobeNewswireQuarter highlighted by the key acquisition of The Sleep Center of Nevada, which is generating revenue and seeing strong patient demand for Vivos' differentiated array of highly effective OSA treatments Management to
1y agoVVOSVivos Therapeutics Schedules Release of Second Quarter 2025 Financial Results and Conference CallGlobeNewswireLITTLETON, Colo., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and
1y agoVVOSVivos Therapeutics Adds to Management Team to Support Expansion and GrowthGlobeNewswireLITTLETON, Colo., July 30, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (NASDAQ:VVOS) ("Vivos" or the "Company"), a pioneering medical technology company revolutionizing the treatment of obstructive sleep apnea
1y agoVVOSVivos Therapeutics Receives Medicare Approval for VidaSleep™ Oral ApplianceGlobeNewswireLITTLETON, Colo., July 01, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (NASDAQ:VVOS) ("Vivos" or the "Company"), a pioneering medical technology company revolutionizing the treatment of obstructive sleep apnea
1y agoVVOSNew Clinical Trial Data Published Showing Positive Results from Use of Vivos Technology to Treat Obstructive Sleep Apnea in ChildrenGlobeNewswireLITTLETON, Colo., June 26, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leader in proprietary, non-invasive treatments for obstructive sleep apnea (OSA), today announced
1y agoVVOSVivos Therapeutics Completes Acquisition of The Sleep Center of NevadaGlobeNewswireTransaction brings OSA diagnostic revenue to Vivos, plus Vivos' highly effective OSA treatment options to thousands of potential patients in the greater Las Vegas area Transaction also completes Vivos' business model
1y agoVVOSVivos Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational UpdateGlobeNewswireYear-over-year product revenue increased 8%, and year-over-year operating expenses decreased 5% as Vivos sets the stage for its Sleep Center of Nevada acquisition and continued advancement of its new marketing and
1y agoVVOSVivos Therapeutics Schedules Release of First Quarter 2025 Financial Results and Conference CallGlobeNewswireLITTLETON, Colo., May 14, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and
1y agoVVOSVivos Therapeutics Signs Definitive Agreement to Acquire Largest Sleep Center Operator in NevadaGlobeNewswireBy acquiring The Sleep Center of Nevada, Vivos expands its business model to make its OSA treatments available to thousands of patients in the greater Las Vegas metro area Acquisition expected to close later this
1y agoVVOSVivos Therapeutics Reports Full Year 2024 Financial Results and Provides Operational UpdateGlobeNewswireYear over year product revenue increased 26% Operating expenses declined 21% and year over year operating loss decreased 35% Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., March 31,
1y agoVVOSVivos Therapeutics Schedules Release of Full Year 2024 Financial Results and Conference CallGlobeNewswireLITTLETON, Colo., March 28, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and
1y agoVVOSVivos Therapeutics Expands Strategic Alliance in Colorado and Seeks New Sleep Center Affiliations and Acquisitions NationwideGlobeNewswireVivos announces immediate expansion of its new alliance model into two additional Colorado locations as initial reports show sleep apnea patients prefer Vivos CARE treatment for OSA nearly 2 to 1 over CPAP Vivos seeking
1y agoVVOSVivos Therapeutics to Participate in Fireside Chat with Water Tower Research on February 18, 2025 at 12:00 pm ET.GlobeNewswireLITTLETON, Colo., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and
1y agoVVOSVivos Therapeutics Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesGlobeNewswireLITTLETON, Colo., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and
1y agoVVOSVivos Therapeutics, Inc. (VVOS) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
1y agoVVOSVivos Therapeutics Reports Third Quarter 2024 Financial Results and Provides Operational UpdateGlobeNewswireRevenue Increased 17% Quarter over Quarter Operating Loss Decreased 27% Management to Host Conference Call Today at 5:00 pm ET LITTLETON, Colo., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc.
1y agoVVOSVivos Therapeutics Schedules Release of Third Quarter 2024 Financial Results and Conference CallGlobeNewswireLITTLETON, Colo., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and
2y agoVVOSVivos Therapeutics Granted CPT® Coverage and Reimbursement Codes for All Vivos CARE Oral Medical Devices From American Medical AssociationGlobeNewswireLITTLETON, Colo., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a medical technology company specializing in the development and commercialization of highly